Plain-English translation of NCT06008860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers at the University of Chicago want to see if Astepro® nasal spray can help people who have just been diagnosed with COVID-19. You would either receive the medication or a placebo (a spray with no active ingredient) and provide saliva samples over 10 days so the team can track how quickly the virus clears from your body and whether your symptoms improve.
COVID-19 can cause weeks of uncomfortable symptoms and keep people away from work and loved ones. Researchers want to know if this medication, which is already approved for allergies, might help reduce how sick people get, how long they stay contagious, and whether it prevents close contacts from catching COVID-19.
You likely qualify if…
You likely don't qualify if…
You will watch a short instructional video and receive written directions on how to use the nasal spray. You'll use the spray as directed (either the active medication or placebo) and follow general wellness guidelines. Over the next 10 days, you'll collect saliva samples every other day at home, report your symptoms using a simple form, and the research team will track how your viral load changes. The entire study takes place at home—no in-person visits needed. The team may also ask about people living with you to see if the medication affects whether they catch COVID-19.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Chicago
Enrollment target
~280 participants
Started
July 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Brandon Baird
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.